Business
Evogene Reports Second Quarter 2020 Financial Results
Conference call and webcast: today, August 5, 9:00 am ET REHOVOT, Israel, Aug. 5, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading
About this update from Evogene Ltd.
[{"type":"text","content":"Conference call and webcast: today, August 5, 9:00 am ET\n\n\nREHOVOT, Israel, Aug. 5, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the second quarter ended June 30, 2020.\nOfer Haviv, Evogene's President and CEO, stated: \"During the second quarter the company announced its new branding, which marks the conclusion to the strategic change the company has been focused on over the past years. With this strategic change, we are aiming to apply our world leading computational biology capabilities to important new market areas in human health and in agriculture. I would like to encourage you to read the press release the company issued regarding the strategic change and rebranding, which can be found on Evogene's revised website. The Evogene group (consisting of Evogene and its subsidiaries) is continuing to make substantial progress towards its 2020 targets.\n\"In parallel to the support Evogene provides its subsidiaries, we continue to develop our technological solutions in order to advance our capabilities and expand into new market segments. To that end, during this second quarter, Evogene announced its participation in the CRISPR-IL consortium to provide an end-to-end artificial intelligence system for genome-editing. The consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program and includes 21 industry and academic leaders in the artificial intelligence and genome editing space. Evogene's Chief Scientific Officer, Dr. Eyal Emmanuel, serves as the chairman of the consortium. Genome editing is a tool that enables genetic changes in a method that may not be considered as GMO (genetically modified organism), and we believe that this revolutionary technology may be a breakthrough for the agricultural market in terms of consumer acceptance. Moreover, this technology has the potential to revolutionize a wide range of life-science based industries,\" continued Mr. Haviv.\nMilestones in the second half of 2020:\nAgPlenus (wholly owned subsidiary focused on ag-chemicals)\nHerbicide program - reach a 'Lead' \nAchieving a \"Lead\" phase indicates that a certain family of chemical compounds has shown efficacy...